2014 was a good year for IRW Consulting. The Nordic contract research organisation (CRO) broadened its customer stock and renewed a number of Master Service Agreements with big clients.
IRW Consulting is a premium full-service CRO with more than 15 years of experience of working with outsourced clinical research. The company conducts projects for virtual biotech companies, medtech companies, big pharma and other CROs.
”Working with the full range of companies, from small start-ups to multi-national pharmaceutical corporations, we have learned how to tailor our services to the specific needs of our customers,” says Ingela Wiking, CEO of IRW Consulting.
The company has manned offices in Sweden, Denmark, Norway and Finland.
”Local presence ensures adherence to local requirements for submissions to the ethic committees and regulatory authorities. In addition, the knowledge of local language facilitates the communication with all local parties involved in the project thereby avoiding possible misunderstandings and reducing approval process timelines,” she adds.
IRW, who works with all therapy areas, has built an extensive network of clinics throughout all the Nordic countries, as well as the rest of Europe and the US.
”Depending on the customer’s requirements, our staff is either outsourced or works with in-house projects. Our mix of services and the fact that we’re a full-service provider are among our greatest assets. We’re able to take a project through the entire process, from study plans to study report. We cover all the stages of clinical development, from phase I to phase IV, including paediatric and non-interventional studies and all classes of medical device investigations,” tells Ingela Wiking.
A Good Year for IRW
”Last year, we broadened our customer stock, both in the Nordics and globally. We’re happy about the renewal of agreements we’ve made with a number of important customers, and the fact that we got prolonged Master Service Agreements with big clients. We’ve also increased our engagement in global CRO networks.”
Although happy about the outcome for IRW in 2014, Ingela Wiking would liked to have seen a stronger growth in the Swedish life science industry. She would also like to see improved ways of conducting commissioned research within public healthcare.
”If your research demands radiation protection, for example, you need to make a separate application for each clinic involved. That’s not good. The application procedures need to be harmonised. I can see that it’s about to happen, but that it will take some time before it’s a reality.”
She hopes that Sweden’s new structure for clinical research, consisting of a national hub and six regional nodes, will contribute to an increased focus on clinical research in the healthcare sector.
”In the long run, it may contribute to better cooperation between the regions, and a faster and more efficient start-up of studies,” she concludes.